← All trials
NCT04438434
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Jul 31, 2020
- Completion date
- Jul 31, 2020
- First posted
- Jun 18, 2020
- Last posted
- Jun 18, 2020
- Enrollment
- 57
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MilanLead sponsor
- BMG PHARMACollaborator
- University of MilanReponsible party - principal investigator
- University of MilanOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.